Clinical trial news

The acronym MDA is seen alongside a woman speaking with a microphone at a podium.

Biogen has launched a trio of trials to test its new drug candidate for spinal muscular atrophy (SMA), salanersen, which aims to be a more convenient successor to the company’s approved SMA therapy Spinraza (nusinersen). Salanersen would need to be administered just once per year. The biotech…

Graphs and a medicine bottle are used to illustrate clinical trial data.

The first patient has been dosed in a clinical trial testing GB221, a next-generation gene therapy for spinal muscular atrophy (SMA) type 1. “I would like to express our gratitude for the young child and family who were courageous in being the first to accept our investigational gene therapy…

The words

Treatment with a high-dose regimen of Spinraza (nusinersen) was shown to safely improve motor function in children with spinal muscular atrophy (SMA) in the Phase 2/3 DEVOTE clinical trial. Most patients who switched from the originally approved dose to the high-dose regimen experienced improvements in motor function scores,…

The words

Throughout 2025, the team at SMA News Today has brought our audience the latest advances in spinal muscular atrophy (SMA), from emerging treatments and clinical trial updates to real-world research. As the year comes to a close, we’ve taken a look back at the top 10 stories that…

Three people look at a tablet.

SMA Europe has launched an online tool designed to help patients, doctors, and others in the spinal muscular atrophy (SMA) community more easily explore ongoing clinical trials across Europe and worldwide. The organization said it aims for the Clinical Trials Finder to become “the go-to global resource”…